Metabolic Complications of HIV and Antiretroviral Therapy: Dyslipidemia, Insulin Resistance, and Cardiovascular Disease

  • Authors: Judith S. Currier, MD, MSc; Risa Hoffman, MD, MPH (More Info)
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 10/10/18 (What's New)

Summary

  • Switching to an integrase inhibitor to manage dyslipidemia appears attractive given the favorable metabolic profile of these agents in therapy-naive patients[Quercia 2015; Sierra-Madero 2010; Lennox 2010; Gallant 2017; Sax 2017]
  • Lipid parameters significantly improved in virologically suppressed patients who switched from a boosted PI to coformulated bictegravir/emtricitabine/tenofovir AF in Study 1878[Daar 2017]
  • Switching from a fully suppressive 3-drug regimen to the 2-drug regimen of dolutegravir/rilpivirine was associated with minimal effects on lipids and cardiovascular biomarkers[Llibre 2018]

Action required